Abstract
The prevalence of urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is increasing and the therapeutic options are limited, especially in primary care. Recent indications have suggested pivmecillinam to be a suitable option. Here, we evaluated the clinical and bacteriological effects of pivmecillinam in UTIs caused by ESBL-producing Enterobacteriaceae.
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Journal of antimicrobial chemotherapy |
Vol/bind | 69 |
Udgave nummer | 3 |
Sider (fra-til) | 769-772 |
Antal sider | 3 |
ISSN | 0305-7453 |
DOI | |
Status | Udgivet - mar. 2014 |